Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/jdv.17177 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting.
J Allergy Clin Immunol Pract
September 2024
Division of Allergy and Immunology, Feinberg School of Medicine, Northwestern University, Chicago, Ill. Electronic address:
Article Synopsis
- Dupilumab is effective for treating asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), but can cause eosinophilia (high eosinophil counts) in some patients.
- In a study of 251 patients, 11.3% developed eosinophilia after starting dupilumab, but most experienced no significant adverse effects related to it.
- Despite the presence of eosinophilia, many patients still achieved significant treatment benefits, suggesting dupilumab remains a viable option for asthma and CRSwNP management.
Dupilumab-associated hypereosinophilia in severe asthma.
ERJ Open Res
July 2024
Allergy, Asthma and Clinical Immunology Service, Alfred Health, Melbourne, Australia.
https://bit.ly/3JgZ5Ya.
View Article and Find Full Text PDFDupilumab-associated (hyper)eosinophilia in patients with atopic dermatitis: a single-centre cohort study of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Br J Dermatol
November 2024
Department of Dermatology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Bronchial asthma and chronic polypous rhinosinusitis are diseases associated with a T2-inflammatory immune response. These nosologies can be combined, creating the preconditions for a more severe course of multimorbidity, requiring the use of genetic engineering biological therapy. Dupilumab is a monoclonal antibody that can specifically bind to the alpha subunit of the interleukin-4 receptor and block the action of interleukins 4 and 13, which play a key role in the development of T2 inflammation.
View Article and Find Full Text PDFThe clinical significance of dupilumab-induced blood eosinophil elevation in Japanese patients with atopic dermatitis.
Drug Discov Ther
September 2022
Department of Dermatology, Wakayama Medical University, Wakayama, Japan.
This study aims to clarify the clinical significance of dupilumab-induced elevation of blood eosinophil in Japanese patients with atopic dermatitis (AD). Eosinophil elevation was defined as ≥ 5% increase of eosinophil percentage within one year after dupilumab initiation. Seven patients (15.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!